What is MaxCyte?
MaxCyte operates as a clinical-stage company dedicated to bringing the promise of cell-based medicine to patients. Its proprietary cell engineering platform is central to its mission, enabling the development of therapies for conditions with significant unmet medical needs. The company's focus on life sciences positions it at the forefront of therapeutic innovation, leveraging advanced biological engineering to create novel treatment modalities.
How much funding has MaxCyte raised?
MaxCyte has raised a total of $77.3M across 6 funding rounds:
Series A
$8M
Series B
$10.7M
Stock Offering
$14.4M
Share Placement
$12.3M
Debt
$1M
Share Placement
$30.9M
Series A (2003): $8M with participation from Undisclosed
Series B (2004): $10.7M led by Tall Oaks Capital, Harbert Venture Partners, and Intersouth Partners
Stock Issuance/Offering (2016): $14.4M supported by Undisclosed
Share Placement (2019): $12.4M featuring Undisclosed
Debt (2020): $1M backed by PPP
Share Placement (2020): $30.9M with participation from Sofinnova Crossover and Casdin Capital
Key Investors in MaxCyte
Tall Oaks Capital
Tall Oaks Capital is an investment firm focused on early-stage companies in the Mid-Atlantic and Southeastern U.S., with a particular interest in technology and life sciences, often partnering with research universities.
Harbert Venture Partners
Harbert Venture Partners, part of Harbert Management Corporation, specializes in private equity investments across various sectors including technology and life sciences, with a focus on middle-market and later-stage companies.
Casdin Capital
Casdin Capital is a venture capital firm dedicated to financing life science innovation, with a notable portfolio in diagnostics and molecular information, including investments in pioneering companies in the field.
What's next for MaxCyte?
The recent major strategic investment signals a critical growth phase for MaxCyte, likely enabling the company to accelerate its clinical development pipeline, expand its research and development capabilities, and potentially scale its manufacturing operations. This infusion of capital, coupled with the company's established cell engineering platform, suggests a strategic push towards commercialization and broader market penetration. MaxCyte's trajectory indicates a strong focus on translating its technological advancements into tangible patient benefits, positioning it as a key player in the evolving landscape of cell-based therapies.
See full MaxCyte company page
